Publication:
Trastuzumab ± capecitabine maintenance after the first-line treatment of HER2-positive advanced gastric cancer: Retrospective observational real-life data of Turkish oncology group

dc.contributor.authorGürbüz, Mustafa
dc.contributor.authorAkkuş, Erman
dc.contributor.authorSakin, Abdullah
dc.contributor.authorUrvay, Semiha
dc.contributor.authorDemiray, Atike Gökçen
dc.contributor.authorŞahin, Süleyman
dc.contributor.authorSakalar, Teoman
dc.contributor.authorErol, Cihan
dc.contributor.authorŞendur, Mehmet Ali Nahit
dc.contributor.authorŞahin, Ahmet Bilgehan
dc.contributor.authorÇubukcu, Erdem
dc.contributor.authorGuven, Deniz Can
dc.contributor.authorKılıçkap, Saadettin
dc.contributor.authorErgün, Yakup
dc.contributor.authorUncu, Doğan
dc.contributor.authorTurhal, Nazim Serdar
dc.contributor.authorUskent, Necdet
dc.contributor.authorÇınkır, Havva Yeşil
dc.contributor.authorDemir, Atakan
dc.contributor.authorAcar, Ramazan
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorTürker, Sema
dc.contributor.authorAltınbaş, Mustafa
dc.contributor.authorKaraoğlan, Mert
dc.contributor.authorŞenler, Filiz Çay
dc.contributor.buuauthorŞAHİN, AHMET BİLGEHAN
dc.contributor.buuauthorÇUBUKÇU, ERDEM
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.
dc.contributor.orcid0000-0002-7846-0870
dc.contributor.orcid0000-0002-0070-0889
dc.contributor.researcheridAAM-4927-2020
dc.contributor.researcheridJGT-4101-2023
dc.date.accessioned2024-06-12T06:13:29Z
dc.date.available2024-06-12T06:13:29Z
dc.date.issued2021-01-24
dc.description.abstractPurpose In the ToGA trial for HER2-positive advanced gastric cancer, cisplatin plus fluoropyrimidine was given for 6 cycles; trastuzumab was given until disease progression. However, there is a lack of real-life data about trastuzumab maintenance after 6 cycle chemotherapy. This study aims to present real-life data of trastuzumab +/- capecitabine maintenance after 6 cycles of platinum, fluoropyrimidine, and trastuzumab in non-progressive patients. Methods This is a retrospective multicenter study of the Turkish Oncology Group. A total of 35 HER2-positive, inoperable locally advanced, recurrent, or metastatic gastric adenocarcinoma patients being non-progressive at the end of 6 cycle chemotherapy and being given trastuzumab +/- capecitabine as maintenance treatment were included from sixteen oncology centers. Baseline characteristics, objective tumor responses, progression free and overall survival data, and toxicities were determined. Results About 68% of the patients were given CF, and 32% were given FOLFOX with trastuzumab as the first-line treatment. The best response in 6 cycle chemotherapy was complete 8 (22%), partial 24 (68%), and stable disease 3 (8%). All patients had trastuzumab maintenance (median cycle 13; range 7-51), and 49% of the patients had capecitabine with trastuzumab (median capecitabine cycle 6; range 2-30). The median PFS of the patients was 12.0 months (95% CI 10.3-13.7), and median OS was 17.4 months (95% CI 15.2-19.5). There were 2 patients with grade 1 cardiotoxicity. Conclusion Trastuzumab maintenance +/- capecitabine after 6 cycles of trastuzumab plus combined chemotherapy treatment revealed efficacy and safety in non-progressive HER2-positive advanced gastric cancer.
dc.identifier.doi10.1007/s12029-021-00594-1
dc.identifier.eissn1941-6636
dc.identifier.endpage288
dc.identifier.issn1941-6628
dc.identifier.issue2
dc.identifier.startpage282
dc.identifier.urihttps://doi.org/10.1007/s12029-021-00594-1
dc.identifier.urihttps://link.springer.com/article/10.1007/s12029-021-00594-1
dc.identifier.urihttps://hdl.handle.net/11452/42022
dc.identifier.volume53
dc.identifier.wos000614703600001
dc.indexed.wosWOS.ESCI
dc.language.isoen
dc.publisherSpringer
dc.relation.journalJournal of Gastrointestinal Cancer
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectPhase-ii
dc.subjectCombination
dc.subjectAdenocarcinoma
dc.subjectMulticenter
dc.subjectOxaliplatin
dc.subjectCisplatin
dc.subjectHER2
dc.subjectS-1
dc.subjectGastric cancer
dc.subjectTrastuzumab
dc.subjectChemotherapy
dc.subjectMaintenance
dc.subjectOncology
dc.subjectGastroenterology & hepatology
dc.titleTrastuzumab ± capecitabine maintenance after the first-line treatment of HER2-positive advanced gastric cancer: Retrospective observational real-life data of Turkish oncology group
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication4dc703eb-05b2-4b24-b6ad-dcaca00b36d9
relation.isAuthorOfPublicationf971677f-09c5-4463-bf01-3c6341fbe5f7
relation.isAuthorOfPublication.latestForDiscovery4dc703eb-05b2-4b24-b6ad-dcaca00b36d9

Files

Collections